Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Aclaris Therapeutics (ACRS) EBITDA Margin: 2017-2025

Historic EBITDA Margin for Aclaris Therapeutics (ACRS) over the last 8 years, with Sep 2025 value amounting to -439.50%.

  • Aclaris Therapeutics' EBITDA Margin fell 28542.00% to -439.50% in Q3 2025 from the same period last year, while for Sep 2025 it was -898.93%, marking a year-over-year decrease of 76803.00%. This contributed to the annual value of -704.39% for FY2024, which is 42377.00% down from last year.
  • As of Q3 2025, Aclaris Therapeutics' EBITDA Margin stood at -439.50%, which was up 49.22% from -865.56% recorded in Q2 2025.
  • In the past 5 years, Aclaris Therapeutics' EBITDA Margin ranged from a high of -2.66% in Q4 2023 and a low of -1,622.58% during Q2 2023.
  • In the last 3 years, Aclaris Therapeutics' EBITDA Margin had a median value of -717.22% in 2024 and averaged -697.79%.
  • Within the past 5 years, the most significant YoY rise in Aclaris Therapeutics' EBITDA Margin was 122,182bps (2024), while the steepest drop was 104,914bps (2024).
  • Over the past 5 years, Aclaris Therapeutics' EBITDA Margin (Quarterly) stood at -1,533.98% in 2021, then soared by 118,486bps to -349.12% in 2022, then surged by 34,645bps to -2.66% in 2023, then tumbled by 104,914bps to -1,051.81% in 2024, then crashed by 28,542bps to -439.50% in 2025.
  • Its last three reported values are -439.50% in Q3 2025, -865.56% for Q2 2025, and -1,013.61% during Q1 2025.